Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Exploring Innovative Approaches Throughout the CGT Development Journey
A Concise Report Featuring Insights From The Prominent Thought Leaders Of Cell UK
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Cell-based Therapies
University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus
The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK.
Antibody-based Therapies
Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants
The phase IIb/III met both its primary and secondary endpoints in infants one year old or younger.
Regulatory
The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine
The National Institute of Standards and Technology (NIST) has given $1.5 million to two organisations to enhance regenerative medicine standards.
NextGen Therapeutics
Archon Biosciences Announces $20m of Seed Funding for its Nobel-Winning, AI-Driven Antibody Cage Technology
This investment signals the UW spin out’s ‘emergence from stealth’, showcasing their unique antibody platform.
Antibody-based Therapies
FDA Grant Rare Pediatric Disease Designation to Omeros’s Antibody for C3 Glomerulopathy
Rare pediatric disease designation allows the company to access priority review from the FDA for a new drug application or biologics licence application.
Medicinal Chemistry
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
3D Cell Culture
MicroQuin’s Space-Based Research Uncovers New Pathways in Cancer Treatment
MicroQuin has teamed up with the International Space Station to explore the behaviour of cancer cells in space and the implications this could have for developing new treatments.
Immunotherapy (Non-Oncology)
Phase II Trial Begins for Recombinant Gelsolin as Immune Regulator in ARDS Patients
BioAegis’s recombinant human plasma gelsolin aims to address the inflammatory complications of ARDS.